Inactive

*****Questions and Reponses dated 18 Nov 20 have been potested for review***** Request for Project Proposals W911QY-21-S-Med1 Contracting Agency: Department of the Army Contracting Office: Army Contra... *****Questions and Reponses dated 18 Nov 20 have been potested for review***** Request for Project Proposals W911QY-21-S-Med1 Contracting Agency: Department of the Army Contracting Office: Army Contracting Command, Natick Contracting Division (NCD) Contracting Office Location: Fort Detrick, MD, USA Program Office: JPEO CBRND JPM CBRN Medical RPP Number: W911QY-21-S-Med1 Date Issued: 13 Nov 2020 Proposals Due: 20 Nov 2020 by 11:59PM EST 1. Establish and conduct a randomized, adaptive placebo-controlled Phase II/III clinical study of the anti-TNF? therapeutic (Humira® [adalimumab] 160 mg) in adult patients with COVID-19 disease in an outpatient setting. The goal of this prototype project is to evaluate the technical feasibility of this treatment in support of a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and/or licensure of the adalimumab for this new indication against COVID-19. 2. The Government is hereby requesting formal submission of proposals to execute a formal agreement under 10 USC 2371(b), Other Transaction Authority (OTA) for the prototype project described above Full RPP is attached to this announcement.